Get the Stockscreener App
29.85
0.03%
-0.010
After Hours:
28.65
-1.20
-4.02%
Newamsterdam Pharma Company Nv stock is traded at $29.85, with a volume of 885.49K.
It is down -0.03% in the last 24 hours and down -9.52% over the past month.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
See More
Previous Close:
$29.86
Open:
$29.95
24h Volume:
885.49K
Relative Volume:
1.03
Market Cap:
$3.43B
Revenue:
$22.50M
Net Income/Loss:
$-203.82M
P/E Ratio:
-17.09
EPS:
-1.7469
Net Cash Flow:
$-148.03M
1W Performance:
+3.93%
1M Performance:
-9.52%
6M Performance:
-21.70%
1Y Performance:
+47.48%
1-Day Range:
$29.10
$31.00
1-Week Range:
$27.93
$31.00
52-Week Range:
$16.79
$42.00
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Name
Newamsterdam Pharma Company Nv
Sector
Industry
Phone
35 206 2971
Address
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
29.85 | 3.43B | 22.50M | -203.82M | -148.03M | -1.7469 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Buy |
| Oct-20-25 | Resumed | H.C. Wainwright | Buy |
| Aug-25-25 | Initiated | Wells Fargo | Overweight |
| Jul-17-25 | Initiated | Goldman | Neutral |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jun-10-25 | Initiated | Stifel | Buy |
| Jun-04-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| May-15-24 | Initiated | TD Cowen | Buy |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-18-24 | Initiated | Guggenheim | Buy |
| Jan-16-24 | Initiated | Piper Sandler | Overweight |
| Oct-30-23 | Initiated | RBC Capital Mkts | Outperform |
View All
Newamsterdam Pharma Company Nv Stock (NAMS) Latest News
(NAMS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Five new hires at NewAmsterdam get stock awards covering 65,800 shares - Stock Titan
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Pictet Asset Management Holding SA Lowers Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Jennison Associates LLC Trims Stock Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
What sustainable investing NewAmsterdam (NAMSW)? (+5.61%) 2026-04-29Community Watchlist - Newser
143,549 Shares in NewAmsterdam Pharma Company N.V. $NAMS Bought by Moody Aldrich Partners LLC - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 8%What's Next? - MarketBeat
NAMSW Price History for Newamsterdam Pharma Company N.V. WT Stock - Barchart.com
Understanding Momentum Shifts in (NAMSW) - Stock Traders Daily
NewAmsterdam Pharma Company N.V. Files 8-K with SEC: Company Information, NASDAQ Listing, and Key Filing Details - Minichart
NewAmsterdam Pharma Announces Chief Accounting Officer Transition Agreement - TipRanks
NewAmsterdam Pharma (NAMS) details CAO exit, bonus and equity terms - Stock Titan
NAMS (NewAmsterdam Pharma Company N.V. Ordinary Shares) reports wider-than-expected Q4 2025 losses, stock dips 1.25% as revenue halves year-over-year.Most Discussed Stocks - Xã Thanh Hà
NewAmsterdam Pharma Co. NV Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
NAMS (NewAmsterdam Pharma Company N.V. Ordinary Shares) posts wider than expected Q4 2025 loss, shares rise 4.46 percent on upbeat investor sentiment.Social Momentum Signals - Cổng thông tin điện tử tỉnh Tây Ninh
NAMSW (NewAmsterdam) does not disclose core quarterly earnings metrics as investors await further operational guidance details.Growth Pick - Cổng thông tin điện tử tỉnh Tây Ninh
Price-Driven Insight from (NAMS) for Rule-Based Strategy - Stock Traders Daily
What is limiting NewAmsterdam (NAMS) stock performance (Breakout Watch) 2026-04-20Community Risk Signals - Xã Thanh Hà
NewAmsterdam Pharma (NAMS) AGM June 2, 2026: ESPP, auditors, director votes - Stock Titan
Avoiding Lag: Real-Time Signals in (NAMSW) Movement - Stock Traders Daily
NewAmsterdam Pharma: Cholesterol-Lowering Player Is A Risk-On Buy Today (NASDAQ:NAMS) - Seeking Alpha
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Resistance Check: What are the risks of holding NewAmsterdam Pharma Company NV Equity WarrantQuarterly Trade Review & Real-Time Buy Zone Alerts - baoquankhu1.vn
NewAmsterdam Pharma Company (NAMS): Huge upside potential grabs attention of billionaire Stan Druckenmiller - MSN
Pullback Watch: What are the risks of holding NewAmsterdam Pharma Company NV Equity Warrant2026 Fed Impact & Weekly Return Optimization Plans - baoquankhu1.vn
(NAMS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Published on: 2026-04-11 17:21:30 - baoquankhu1.vn
NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference - Sahm
A Look At NewAmsterdam Pharma (NAMS) Valuation As Hedge Funds Focus On Obicetrapib’s Phase 3 LDL C Results - Yahoo Finance
NewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan Druckenmiller - Insider Monkey
Gains Report: Will NewAmsterdam Pharma Company NV Equity Warrant benefit from AI trendsEntry Point & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Does NewAmsterdam Pharma (NAMS) CETP Optimism Point To A Durable Edge In Cardiovascular Treatment? - Sahm
Short Squeeze: Will NewAmsterdam Pharma Company NV stock recover after earnings2026 Retail Activity & Weekly High Return Forecasts - baoquankhu1.vn
Billionaire Stan Druckenmiller’s 5 Small and Mid-Cap Stock Picks with Huge Upside Potential - Insider Monkey
Is NewAmsterdam (NAMSW) Stock Attractive Now | Price at $23.71, Up 12.53%Expert Momentum Signals - Xã Châu Thành
Aberdeen Group plc Has $25.59 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Is NewAmsterdam (NAMS) Stock a Good Buy in 2026 | Price at $33.00, Up 0.03%Social Buy Zones - Xã Vĩnh Công
Discipline and Rules-Based Execution in NAMSW Response - Stock Traders Daily
Will NewAmsterdam Pharma Company NV benefit from seasonality2026 Key Highlights & Trade Opportunity Analysis - baoquankhu1.vn
NAMS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
NAMS Stock Analysis: NewAmsterdam Pharma 0.55 pct daily gain 32.99 price outlook - UBND thành phố Hải Phòng
Two new hires get 15,000 stock options and 3,200 RSUs at NewAmsterdam - Stock Titan
Here’s Why NewAmsterdam Pharma Company N.V. (NAMS) Surged 23% in Q4 - Insider Monkey
NAMSW SEC FilingsNewAmsterdam Pha 10-K, 10-Q, 8-K Forms - Stock Titan
Pullback Watch: Is NewAmsterdam Pharma Company NV Equity Warrant stock trending bullish2026 Buyback Activity & Daily Technical Forecast Reports - baoquankhu1.vn
(NAMS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Revenue Check: Does NewAmsterdam Pharma Company NV have declining or rising EPSWeekly Gains Summary & Safe Entry Trade Reports - baoquankhu1.vn
Will ACC.26 Obicetrapib Data on Kidney, Safety and Lipids Change NewAmsterdam Pharma's (NAMS) Narrative? - Sahm
Newamsterdam Pharma Company Nv Stock (NAMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):